Latest Stock Buy or Sell?

Today, Stockchase Insights and Jim Cramer - Mad Money commented about whether CZR-Q, RSG-N, SWBI-Q, CIEN-N, GEO-N, MCS-N, ACI-N, LLY-N, NCLH-N, AAPL-Q, AGG-N, FNV-T, BLX-T are stocks to buy or sell.


Billy Kawasaki’s Insights - Picks from 5i Research. A renewable power producer. It has done well although it is expensive, trading around 71x earnings. They enjoy good earnings prospects and sales have doubled in past years. They have a lot of debt but cash flow is growing quickly. An aggressive choice in the sector. Unlock Premium - Try 5i Free

electrical utilities

Billy Kawasaki’s Insights - Picks from 5i Research. There was some sell off with large volume last week. The stock is still up 51% this year and is currently trading at levels similar to late June. There has been no corporate news. Unlock Premium - Try 5i Free

precious metals

Billy Kawasaki’s Insights - Picks from 5i Research. With the Fed stating that low interest rates are here for a while, this stock should perform fine. It has 20% exposure to long maturities which could pose some risk. One of the best in its category. Unlock Premium - Try 5i Free

Forget about a lack of further stimulus; there could be a US government shut down next month. Small businesses in restaurants and bars need financial help the most. Many will go out of business. Airlines and the travel sector also need a bail-out. House-buying is booming, but apartment renters are sinking. With the US election looming and Trump threatening to immediately replace Ruth Bader Ginsburg on the Supreme Court, there are jitters among investors, enough that he urges them to hold (not sell) stocks.
As stocks slid today, there was a silver lining in some tech name. Apple rallied to finish 3% positive. We're in the middle of a tech sell-off in September. Don't sell tech now, but buy.
electrical / electronic
NCLH has enough cash to last two years and the CEO knows how to raise capital. There's a lot of panicking among travel stocks, lots of selling, so take advantage and buy into that panic. This is a buy if you have a two-year outlook.
They just released very promising data on their breast cancer drug (the previous update in June saw the stock pop), but the stock still dropped in price today. This is strange and undeserved, but the selling won't last.
biotechnology / pharmaceutical